Thursday, May 12, 2011
NanoBio Corp., of Ann Arbor, Mich., began two Phase III trials of NB-001 for cold sores, as part of its 2009 licensing agreement with GlaxoSmithKline Consumer Healthcare, a division of GlaxoSmithKline plc, of London. The trials will enroll a total of 1,700 subjects at 72 clinical sites, and are expected to conclude in 2012.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.